Pfizer Inc. (NYSE:PFE) Shares Sold by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 35.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 29,608 shares of the biopharmaceutical company’s stock after selling 15,975 shares during the period. Landscape Capital Management L.L.C.’s holdings in Pfizer were worth $786,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. United Bank increased its position in shares of Pfizer by 3.7% in the third quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock valued at $1,030,000 after buying an additional 1,277 shares in the last quarter. Janus Henderson Group PLC increased its holdings in Pfizer by 0.5% during the 3rd quarter. Janus Henderson Group PLC now owns 530,429 shares of the biopharmaceutical company’s stock valued at $15,348,000 after acquiring an additional 2,600 shares in the last quarter. Kovitz Investment Group Partners LLC raised its position in Pfizer by 35.4% during the third quarter. Kovitz Investment Group Partners LLC now owns 366,690 shares of the biopharmaceutical company’s stock worth $10,612,000 after acquiring an additional 95,896 shares during the last quarter. Hendershot Investments Inc. lifted its holdings in shares of Pfizer by 12.7% in the third quarter. Hendershot Investments Inc. now owns 24,895 shares of the biopharmaceutical company’s stock valued at $720,000 after purchasing an additional 2,798 shares in the last quarter. Finally, DF Dent & Co. Inc. grew its position in shares of Pfizer by 11.9% in the third quarter. DF Dent & Co. Inc. now owns 45,708 shares of the biopharmaceutical company’s stock valued at $1,323,000 after purchasing an additional 4,852 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.06% of the company’s stock.

Pfizer Trading Down 5.4 %

Shares of PFE opened at $22.99 on Friday. The stock’s fifty day simple moving average is $25.87 and its 200 day simple moving average is $26.74. Pfizer Inc. has a twelve month low of $22.95 and a twelve month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $130.39 billion, a P/E ratio of 16.31, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company’s revenue was up 24.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.10 EPS. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on PFE shares. Bank of America reaffirmed a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, Truist Financial lowered their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.